www.fdanews.com/articles/67483-chronogen-announces-a-partnership-with-sosei-for-the-screening-of-the-sosei-drug-reprofiling-platform-compound-library
CHRONOGEN ANNOUNCES A PARTNERSHIP WITH SOSEI FOR THE SCREENING OF THE SOSEI DRUG REPROFILING PLATFORM COMPOUND LIBRARY
January 12, 2005
Chronogen, a drug discovery company developing therapeutics to treat age-dependent diseases has announced an agreement with Sosei, a leading Japanese biopharmaceutical company focused on drug development. Under this agreement, Chronogen will screen the library of Sosei's Drug Reprofiling Platform in a variety of Chronogen's proprietary, phenotype- based, in vivo screening assays in the nematode C. elegans. For its Drug Reprofiling Platform, Sosei has acquired a collection of drugs from a number of Japanese pharmaceutical companies.